REGN 2810

Drug Profile

REGN 2810

Alternative Names: PD-1 protein inhibitor - Regeneron; REGN2810; SAR 439684

Latest Information Update: 22 Jun 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Small cell lung cancer
  • Phase I B cell lymphoma; Cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 04 Jun 2017 Adverse events and efficacy data from a phase I trial in cutaneous squamous cell carcinoma presented at the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
  • 30 May 2017 Phase-III clinical trials in Non-small cell lung cancer (Monotherapy, First-line therapy, Late-stage disease, Metastatic disease) in Georgia, Turkey (Parenteral) (NCT03088540)
  • 08 May 2017 Inovio Pharmaceuticals and Regeneron Pharmaceuticals enter into clinical agreement for conducting a phase I/II study in Glioblastoma (Newly diagnosed, Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top